"Patience is a Super Power" - "The Money is in the waiting"
Showing posts with label investments. Show all posts
Showing posts with label investments. Show all posts

Tuesday, November 17, 2026

An Alternative to an Uncertain AI Trade - medicine and, in particular, Genetics

 


Investment Note: Gene editing in focus

Why I like BEAM, CRSP and NTLA 

The Next Medical Revolution — and an Alternative to an Uncertain AI Trade

November 16, 2026 | Investment horizon: 2027–2028

A potentially historic turning point in medicine

Over the past several years, much of the investment world's attention and capital has been concentrated on artificial intelligence, semiconductors, data centres and the enormous infrastructure required to support them.

While AI will undoubtedly remain an important technological revolution, I believe another transformation is unfolding that may ultimately prove just as significant to humanity: the ability to treat, correct and potentially cure serious diseases by editing human genes.

This is no longer simply theoretical science.

Three publicly traded biotechnology companies—Beam Therapeutics (NASDAQ: BEAM), CRISPR Therapeutics (NASDAQ: CRSP) and Intellia Therapeutics (NASDAQ: NTLA)—are approaching important milestones that could help move genetic medicine from specialized experimental treatments toward broader commercial adoption.

Two years ago I took positions in all three, with BEAM as my principal investment, CRSP as the more commercially established complement and NTLA as the higher-risk, potentially higher-reward opportunity. I exited those positions in favor of the Ai buildout trade.  I am now considering entering positions again.

1. Beam Therapeutics (BEAM): My first choice

Beam is developing base editing, a technology designed to make precise changes to individual DNA letters without requiring the conventional double-strand DNA cuts associated with earlier CRISPR approaches.

This potentially provides a more precise way of addressing the genetic causes of disease.

On November 10, 2026, Beam announced positive pivotal results for risto-cel, its investigational sickle-cell treatment. The trial met its primary efficacy and safety endpoints, and the company expects to submit its FDA application as early as year-end 2026.

Equally important is BEAM-302, which aims to correct the underlying genetic defect responsible for alpha-1 antitrypsin deficiency, a serious inherited condition affecting the lungs and liver. Early clinical evidence suggests the treatment is producing the intended biological effects.

Beam reported approximately US$1 billion in cash and marketable securities at September 30, 2026. Its projected funding runway extends into mid-2029, including a conditional financing draw.

Why I am interested: Beam combines a potentially revolutionary technology platform with increasingly convincing clinical evidence, several development programs and sufficient financial resources to pursue major milestones.

I also believe its proprietary technology could make it an attractive strategic acquisition candidate for a larger pharmaceutical company seeking to expand into genetic medicine.

2. CRISPR Therapeutics (CRSP): The commercial validation

CRISPR Therapeutics has already achieved something that many biotechnology companies spend decades pursuing: bringing a gene-editing medicine to market.

Its CASGEVY treatment, developed with Vertex Pharmaceuticals, is approved for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia.

CASGEVY generated approximately US$99 million in product revenue during the third quarter of 2026, representing 30% sequential growth. More than 750 patients worldwide had initiated treatment.

CRSP is also developing CTX310, an investigational in-body gene-editing treatment targeting serious lipid disorders. If successful, its applications could extend beyond rare genetic diseases into much larger cardiovascular markets.

The company reported approximately US$2.28 billion in cash and marketable securities, although part of that balance reflects convertible-debt financing.

Why I am interested: CRSP provides tangible evidence that gene-editing medicine can become a commercial business. Its substantial financial resources, expanding pipeline and relationship with Vertex strengthen the long-term investment case.

A potential acquisition by Vertex or another pharmaceutical company is conceivable, although existing partnerships may reduce the need for a full takeover.

3. Intellia Therapeutics (NTLA): The potentially historic catalyst

Intellia may be approaching one of the most consequential regulatory milestones in genetic medicine.

Its investigational lonvo-z treatment is designed to provide a one-time therapy for hereditary angioedema, a serious disorder that causes recurrent swelling attacks.

In Phase 3 testing, the treatment reduced attacks by approximately 87% compared with placebo over six months.

The FDA has accepted Intellia's application, with a target decision date of March 10, 2027.

If approved, lonvo-z could become the world's first commercially approved treatment that uses CRISPR to edit genes directly inside the human body.

That distinction is enormously important. Rather than removing cells, modifying them in a laboratory and returning them to the patient, in-body gene editing offers the prospect of simpler treatment delivery for certain diseases.

Intellia also has a strategic relationship with Regeneron Pharmaceuticals.

Why I am interested: NTLA offers the possibility of a major regulatory and commercial breakthrough within months. Its comparatively smaller market capitalization could make successful commercialization particularly meaningful to shareholders.

However, the company has experienced safety concerns in a separate gene-editing program, and FDA approval is not assured. I would therefore treat NTLA as the smallest and most speculative of the three investments.

4. Why Big Pharma could become interested

Large pharmaceutical companies face a continuing challenge: important medicines eventually lose patent protection, exposing billions of dollars in annual revenue to generic and biosimilar competition.

Acquiring innovative biotechnology companies is one way to replenish their development pipelines and obtain technologies that could underpin future generations of treatments.

Gene editing is especially attractive because it offers the possibility of treating diseases at their genetic source rather than managing symptoms indefinitely.

I see three potential reasons for acquisition interest:

  • Proprietary technology: A successful gene-editing platform could generate numerous future medicines, making the technology itself strategically valuable.

  • Clinical and regulatory validation: As treatments demonstrate efficacy and obtain approvals, some of the uncertainty facing potential acquirers diminishes.

  • Access to new markets: Successful gene-editing therapies for cardiovascular, metabolic and other widespread diseases could create much larger commercial opportunities than today's initial rare-disease applications.

Beam's base-editing platform, CRSP's approved treatment and Intellia's in-body editing capabilities each represent different strategic opportunities.

Existing relationships involving Pfizer, Eli Lilly, Vertex and Regeneron illustrate the pharmaceutical industry's interest in these technologies.

I consider Beam the most interesting potential acquisition candidate, followed by Intellia and CRISPR Therapeutics. This is a judgment about strategic attractiveness, not evidence of current acquisition discussions.

Importantly, my investment thesis does not depend on a takeover. These businesses must ultimately create value through successful medicines, commercialization and sustainable economics.

5. Why consider these investments now, amid the Nvidia controversy?

The timing of this opportunity is particularly interesting.

Nvidia's co-founder Jensen Huang resigned in November following reports concerning his personal conduct and allegations involving a suspected foreign-intelligence connection.

The controversy has raised questions about corporate governance, leadership succession and Nvidia's future strategic direction. The intelligence-related allegations remain unproven, and Nvidia has stated that it has no reason to believe company secrets were compromised.

More broadly, investors are increasingly questioning the financial structure supporting the AI infrastructure boom.

Enormous capital commitments, complex financing arrangements, circular investment relationships and uncertainty about future returns on AI spending have created concern about whether the market has become excessively dependent on a relatively small number of technology companies.

I do not believe this necessarily means the AI revolution is ending.

However, a temporary correction in AI-related equities could encourage investors to reconsider where the next major technological and commercial opportunities will emerge.

Genetic medicine offers a compelling alternative.

Unlike an AI infrastructure investment, whose immediate financial prospects may depend on continued data-centre construction and semiconductor spending, biotechnology companies can experience substantial valuation changes following successful clinical trials, FDA approvals and commercial adoption.

Their catalysts are different.

This does not make biotechnology immune to market corrections. Smaller biotechnology stocks are often highly sensitive to interest rates, liquidity and investor risk appetite. A broad technology selloff could initially drag biotechnology shares lower as well.

Nevertheless, over a two-year horizon, I believe successful genetic-medicine companies could develop investment momentum based on their own medical and commercial achievements, rather than the trajectory of AI infrastructure spending.

6. My proposed investment approach

I favour taking positions gradually rather than attempting to predict the precise bottom in any of these stocks.

Within a dedicated speculative genetic-medicine allocation, my preferred weighting would be:

CompanyAllocationInvestment role
BEAM45%Primary technology and growth position
CRSP40%Commercial validation and broader pipeline
NTLA15%Higher-risk regulatory and takeover optionality

I would initially establish partial positions and retain capital to take advantage of market weakness or additional clinical evidence.

There are meaningful risks: disappointing trial results, regulatory setbacks, unexpected safety problems, expensive commercialization, dilution and prolonged operating losses. The three companies also share substantial exposure to the same emerging field, making this a concentrated investment rather than a diversified healthcare portfolio.

7. My investment conclusion

I believe we may be approaching an important inflection point in genetic medicine.

For decades, many inherited diseases could be managed but not fundamentally corrected. Today, companies such as Beam, CRISPR Therapeutics and Intellia are demonstrating that this limitation may increasingly be overcome.

The medical implications are extraordinary, and the commercial implications could be substantial.

At the same time, uncertainty surrounding Nvidia, the financing of the AI infrastructure boom and the concentration of market capital in a handful of technology companies makes it sensible to investigate other sources of long-term growth.

My interest in BEAM, CRSP and NTLA is therefore based on three converging opportunities:

  1. The transition of gene editing from experimental science toward commercial medicine.

  2. The possibility that major pharmaceutical companies will increasingly seek to acquire or partner with developers of proprietary genetic technologies.

  3. The opportunity to diversify growth capital into a potentially transformative industry whose fundamental catalysts differ from those driving the AI infrastructure trade.

I regard BEAM as my first choice, CRSP as my second and NTLA as a smaller, higher-risk third position.

The next 24 months could prove particularly important as regulatory decisions, clinical results and commercialization provide clearer evidence of which companies will become leaders in genetic medicine.

The opportunity is substantial, but success is not assured. I would pursue these investments with a multi-year horizon, disciplined position sizing and a willingness to reassess the thesis as clinical and financial evidence develops.

The central investment proposition is simple: while markets debate the next phase of artificial intelligence, a revolution in the treatment of human disease may already be entering its commercial era.

Investment research note — November 16, 2026. This reflects a speculative investment thesis, not guaranteed returns or confirmed takeover interest.

Research supporting the note

The principal clinical and financial information comes from the companies' November 2026 disclosures: Beam's pivotal clinical results, CRISPR Therapeutics' Q3 results and Intellia's Q3 results.

Beam Therapeutics+2

For the Nvidia discussion, Reuters reports Huang's resignation and the related governance concerns, while distinguishing allegations from established wrongdoing. Reuters also identifies investor scrutiny of AI financing arrangements and Nvidia's leadership transition

Ed Note:

I would not disregard the possible takeover value of these three as their cutting edge technology develops and commercializes. Big Pharma is always on the lookout for such tasty morsels!

Saturday, June 20, 2026

Are you considering precious metals for your TFSA or retirement portfolio?

 

The Precious Metals Reset

Why the Pullback in Silver, Gold and Mining Stocks May Be Creating One of the Best Buying Opportunities of 2026

Executive Summary

Since the early-May highs, both precious metals and mining equities have experienced a significant correction.

Silver has retreated sharply from its peak.

Gold has pulled back from record levels.

Silver miners and gold miners have fallen even more than the underlying metals.

To many investors, this appears bearish.

For long-term investors, (including us) it represents:

A rare opportunity to accumulate strategic assets while the long-term thesis remains intact.

The critical observation is this:

The prices have corrected. The fundamentals largely have not.

In fact, many of the drivers supporting both gold and silver today appear stronger than they were a year ago:

  • Persistent silver supply deficits
  • AI and electrification demand growth
  • Continued central-bank gold buying
  • Geopolitical uncertainty
  • Sovereign debt concerns
  • Currency diversification away from the U.S. dollar
  • Physical metal accumulation by investors and institutions

The result is a compelling setup for investors willing to look beyond the next quarter.


Why Precious Metals Matter More Than Ever

Historically investors separated precious metals into two camps:

Gold = Monetary Metal

Silver = Industrial Metal

Today that distinction is increasingly blurred.

Both metals are becoming strategic assets.

Gold is regaining importance as:

  • a reserve asset
  • a geopolitical hedge
  • a currency diversification tool
  • an inflation hedge

Silver is becoming increasingly critical to:

  • AI infrastructure
  • robotics
  • semiconductors
  • electrical grids
  • EVs
  • aerospace
  • defense technologies

Together, gold and silver now form what may be the world's most important 

hard-asset combination.


Gold: The World's Ultimate Reserve Asset

Gold's investment case has strengthened significantly over the last several years.

Central banks continue to accumulate gold despite record prices.

The World Gold Council reported estimated central-bank purchases of 244 tonnes during Q1 2026, exceeding both the previous quarter and the five-year average.

A recent survey found that a record 45% of central banks expect to increase their gold holdings over the next year.

This matters because central banks represent:

The smartest long-term buyers in the world.

They are not trading.

They are allocating reserves.

Their continued purchases suggest that gold's strategic importance is increasing rather than declining.


Silver: The Technology Metal

Silver may be even more interesting.

Unlike gold, silver has two major demand drivers.

Monetary Demand

  • Wealth preservation
  • Inflation protection
  • Safe-haven buying

Industrial Demand

  • AI infrastructure
  • Robotics
  • Solar energy
  • Electric vehicles
  • Advanced electronics
  • Defense systems

Silver possesses the highest electrical conductivity of any metal.

As AI and electrification expand globally, silver demand continues to benefit from secular growth trends.


The Silver Supply Crisis Remains

This is arguably the strongest part of the silver thesis.

According to the Silver Institute and World Silver Survey 2026, the market is expected to record its sixth consecutive annual deficit. 

Above-ground inventories continue to be drawn down to satisfy demand.

This is important because:

Most silver is not mined for silver.

It is produced as a by-product of:

  • copper mines
  • zinc mines
  • lead mines
  • gold mines

Therefore:

Higher silver prices do not automatically solve the shortage.

This structural issue remains one of the strongest long-term bullish arguments for silver.


Why the Pullback May Be a Gift

The correction since May appears driven largely by:

  • higher bond yields
  • delayed rate-cut expectations
  • stronger U.S. dollar
  • profit taking
  • reduced geopolitical fear

These are cyclical factors.

The long-term drivers are structural.

Historically, some of the best precious-metals investments have been made when:

Prices fall

while

Fundamentals remain strong

That may be the situation today.


Here are Four silver plays we either own or have placed on our watch list!

Sprott Physical Silver Trust

The Silver Foundation

PSLV represents direct ownership of physical silver.

No mining risk.

No cost overruns.

No political issues.

Simply exposure to a strategic metal experiencing persistent deficits.

Why It Matters

If silver ultimately benefits from:

  • AI infrastructure
  • electrification
  • robotics
  • supply shortages

PSLV may become the purest way to participate.


First Majestic Silver Corp.

The High-Torque Silver Vehicle

AG is one of the most recognized silver miners globally.

When silver prices rise, profitability can expand dramatically.

This operational leverage often causes silver miners to outperform the metal itself during bull markets.

Why It Matters

If silver enters a true scarcity-driven bull market:

AG may become one of the largest beneficiaries.


Endeavour Silver Corp.

Growth Plus Silver Leverage

EDR adds something AG does not:

Production growth.

Its Terronera project provides company-specific growth potential in addition to silver exposure.

This creates two possible drivers:

  • higher silver prices
  • increased production

Why It Matters

Few silver miners offer both growth and leverage simultaneously.


XGD

The Gold Allocation

This is where gold enters the story.

XGD owns many of the world's major gold producers.

These companies benefit from:

  • higher gold prices
  • strong margins
  • central-bank demand
  • global reserve diversification

Unlike silver miners, gold producers generally provide:

  • greater stability
  • lower volatility
  • stronger institutional ownership

Why It Matters

Gold remains the world's preferred hard-money asset.

The current correction may be providing investors an opportunity to buy world-class gold producers at more attractive valuations than were available earlier in the year.


Why Gold and Silver Belong Together

Many investors choose one or the other.

Historically, the strongest precious-metals portfolios often own both.

Gold and silver provide different exposures:

AssetPrimary Driver
GoldMonetary demand
SilverIndustrial + monetary demand
Gold MinersGold price leverage
Silver MinersSilver price leverage

Together they create diversification within the precious-metals sector itself.


My Preferred TFSA Allocation Today

For an investor focused on:

  • AI infrastructure
  • silver shortages
  • hard assets
  • tax-free compounding
  • controlled volatility

I would currently favor:

HoldingWeight
PSLV25%
AG25%
EDR20%
XGD30%

Why I Increased XGD

In the earlier report, the emphasis was heavily silver-focused.

Today I believe gold deserves a larger allocation because:

Gold is being accumulated by central banks.

Gold demand remains historically strong.

Gold miners have corrected alongside silver miners.

Gold provides downside protection if economic growth slows.

Meanwhile silver retains its higher upside potential.

This creates a more balanced precious-metals strategy.


The Bull Case Through 2030

If the following continue:

AI Buildout

Robotics Expansion

Grid Electrification

Defense Spending Growth

Central-Bank Gold Accumulation

Ongoing Silver Deficits

Then both gold and silver may remain in secular bull markets.

Several major institutions continue to forecast substantially higher gold prices over the next several years, supported by central-bank buying and reserve diversification.

Meanwhile the silver market continues to face structural shortages and inventory drawdowns.


Bottom Line

The correction since May has likely scared out short-term traders.

But for long-term investors, it may have created something more valuable:

A chance to accumulate both monetary metals and strategic technology metals at lower prices.

Gold is increasingly becoming the world's preferred reserve asset.

Silver is increasingly becoming the world's preferred electrification asset.

And the combination of:

  • PSLV (physical silver)
  • AG (silver torque)
  • EDR (silver growth)
  • XGD (gold stability)

creates a portfolio that is positioned to benefit from both of the defining themes of the next decade:

Hard-money demand

and

Technology-driven resource scarcity.

That is a combination few sectors can currently offer.

Ed Note:  XGD provides a good place to begin our entry point this week


The case for owning silver stocks/ETFs at a time of severe shortages in this precious/technology metal